Global Neuroendocrine Tumor Drug Market Research Report 2025(Status and Outlook)
Neuroendocrine tumors (NETs) are a diverse group of rare, slow-growing neoplasms arising from neuroendocrine cells found throughout the body, most commonly in the gastrointestinal tract, pancreas, and lungs; drugs targeting these malignancies include somatostatin analogs (e.g., octreotide, lanreotide) which control hormone-related symptoms and inhibit tumor growth, targeted therapies like everolimus and sunitinib that interfere with specific molecular pathways involved in tumor proliferation, peptide receptor radionuclide therapy (PRRT) such as lutetium Lu 177 dotatate which delivers radiation directly to tumor cells, and chemotherapy agents like temozolomide and capecitabine used in more aggressive or advanced cases. The market for these therapeutics is characterized by a high unmet medical need due to the rarity and heterogeneity of NETs, leading to diagnostic challenges and delayed treatment initiation; innovation is driven by advancements in precision medicine, biomarker development, and combination therapies, with a growing emphasis on improving progression-free survival and quality of life for patients. Key players include Novartis, Ipsen, Pfizer, and Advanced Accelerator Applications, among others, with regulatory incentives like orphan drug designation fostering research and development in this niche oncology segment.
The global Neuroendocrine Tumor Drug market size was estimated at USD 1845.25 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neuroendocrine Tumor Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neuroendocrine Tumor Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neuroendocrine Tumor Drug market.
Global Neuroendocrine Tumor Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Eisai
ExelixisInc.
Foresee PharmaceuticalsLLC
Hutchison MediPharma Limited
IntezyneInc
INVENT PharmaceuticalsInc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co.Ltd.
Karyopharm TherapeuticsInc.
Lexicon PharmaceuticalsInc.
Midatech Pharma Plc .
Millennium PharmaceuticalsInc.
MolMed S.p.A.
Northwest BiotherapeuticsInc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENEInc.
Market Segmentation (by Type)
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Somatostatin Receptor Antagonists
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Others
Market Segmentation (by Application)
Hospital
Clinic
Others
Geographic Segmentation
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neuroendocrine Tumor Drug Market
Overview of the regional outlook of the Neuroendocrine Tumor Drug Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neuroendocrine Tumor Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neuroendocrine Tumor Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Neuroendocrine Tumor Drug market size was estimated at USD 1845.25 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neuroendocrine Tumor Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neuroendocrine Tumor Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neuroendocrine Tumor Drug market.
Global Neuroendocrine Tumor Drug Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Eisai
ExelixisInc.
Foresee PharmaceuticalsLLC
Hutchison MediPharma Limited
IntezyneInc
INVENT PharmaceuticalsInc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co.Ltd.
Karyopharm TherapeuticsInc.
Lexicon PharmaceuticalsInc.
Midatech Pharma Plc .
Millennium PharmaceuticalsInc.
MolMed S.p.A.
Northwest BiotherapeuticsInc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENEInc.
Market Segmentation (by Type)
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Somatostatin Receptor Antagonists
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Others
Market Segmentation (by Application)
Hospital
Clinic
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neuroendocrine Tumor Drug Market
Overview of the regional outlook of the Neuroendocrine Tumor Drug Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neuroendocrine Tumor Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neuroendocrine Tumor Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neuroendocrine Tumor Drug
1.2 Key Market Segments
1.2.1 Neuroendocrine Tumor Drug Segment by Type
1.2.2 Neuroendocrine Tumor Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEUROENDOCRINE TUMOR DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neuroendocrine Tumor Drug Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEUROENDOCRINE TUMOR DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neuroendocrine Tumor Drug Product Life Cycle
3.3 Global Neuroendocrine Tumor Drug Sales by Manufacturers (2020-2025)
3.4 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neuroendocrine Tumor Drug Market Competitive Situation and Trends
3.8.1 Neuroendocrine Tumor Drug Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neuroendocrine Tumor Drug Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEUROENDOCRINE TUMOR DRUG INDUSTRY CHAIN ANALYSIS
4.1 Neuroendocrine Tumor Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEUROENDOCRINE TUMOR DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neuroendocrine Tumor Drug Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neuroendocrine Tumor Drug Market
5.7 ESG Ratings of Leading Companies
6 NEUROENDOCRINE TUMOR DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
6.3 Global Neuroendocrine Tumor Drug Market Size Market Share by Type (2020-2025)
6.4 Global Neuroendocrine Tumor Drug Price by Type (2020-2025)
7 NEUROENDOCRINE TUMOR DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neuroendocrine Tumor Drug Market Sales by Application (2020-2025)
7.3 Global Neuroendocrine Tumor Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
8 NEUROENDOCRINE TUMOR DRUG MARKET SALES BY REGION
8.1 Global Neuroendocrine Tumor Drug Sales by Region
8.1.1 Global Neuroendocrine Tumor Drug Sales by Region
8.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Region
8.2 Global Neuroendocrine Tumor Drug Market Size by Region
8.2.1 Global Neuroendocrine Tumor Drug Market Size by Region
8.2.2 Global Neuroendocrine Tumor Drug Market Size Market Share by Region
8.3 North America
8.3.1 North America Neuroendocrine Tumor Drug Sales by Country
8.3.2 North America Neuroendocrine Tumor Drug Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neuroendocrine Tumor Drug Sales by Country
8.4.2 Europe Neuroendocrine Tumor Drug Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region
8.5.2 Asia Pacific Neuroendocrine Tumor Drug Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neuroendocrine Tumor Drug Sales by Country
8.6.2 South America Neuroendocrine Tumor Drug Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Region
8.7.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEUROENDOCRINE TUMOR DRUG MARKET PRODUCTION BY REGION
9.1 Global Production of Neuroendocrine Tumor Drug by Region(2020-2025)
9.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
9.3 Global Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neuroendocrine Tumor Drug Production
9.4.1 North America Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.4.2 North America Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neuroendocrine Tumor Drug Production
9.5.1 Europe Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.5.2 Europe Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neuroendocrine Tumor Drug Production (2020-2025)
9.6.1 Japan Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.6.2 Japan Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neuroendocrine Tumor Drug Production (2020-2025)
9.7.1 China Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.7.2 China Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Eisai
10.1.1 Eisai Basic Information
10.1.2 Eisai Neuroendocrine Tumor Drug Product Overview
10.1.3 Eisai Neuroendocrine Tumor Drug Product Market Performance
10.1.4 Eisai Business Overview
10.1.5 Eisai SWOT Analysis
10.1.6 Eisai Recent Developments
10.2 ExelixisInc.
10.2.1 ExelixisInc. Basic Information
10.2.2 ExelixisInc. Neuroendocrine Tumor Drug Product Overview
10.2.3 ExelixisInc. Neuroendocrine Tumor Drug Product Market Performance
10.2.4 ExelixisInc. Business Overview
10.2.5 ExelixisInc. SWOT Analysis
10.2.6 ExelixisInc. Recent Developments
10.3 Foresee PharmaceuticalsLLC
10.3.1 Foresee PharmaceuticalsLLC Basic Information
10.3.2 Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Overview
10.3.3 Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Market Performance
10.3.4 Foresee PharmaceuticalsLLC Business Overview
10.3.5 Foresee PharmaceuticalsLLC SWOT Analysis
10.3.6 Foresee PharmaceuticalsLLC Recent Developments
10.4 Hutchison MediPharma Limited
10.4.1 Hutchison MediPharma Limited Basic Information
10.4.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Overview
10.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Market Performance
10.4.4 Hutchison MediPharma Limited Business Overview
10.4.5 Hutchison MediPharma Limited Recent Developments
10.5 IntezyneInc
10.5.1 IntezyneInc Basic Information
10.5.2 IntezyneInc Neuroendocrine Tumor Drug Product Overview
10.5.3 IntezyneInc Neuroendocrine Tumor Drug Product Market Performance
10.5.4 IntezyneInc Business Overview
10.5.5 IntezyneInc Recent Developments
10.6 INVENT PharmaceuticalsInc.
10.6.1 INVENT PharmaceuticalsInc. Basic Information
10.6.2 INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.6.3 INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.6.4 INVENT PharmaceuticalsInc. Business Overview
10.6.5 INVENT PharmaceuticalsInc. Recent Developments
10.7 Ipsen S.A.
10.7.1 Ipsen S.A. Basic Information
10.7.2 Ipsen S.A. Neuroendocrine Tumor Drug Product Overview
10.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Product Market Performance
10.7.4 Ipsen S.A. Business Overview
10.7.5 Ipsen S.A. Recent Developments
10.8 Jiangsu Hengrui Medicine Co.Ltd.
10.8.1 Jiangsu Hengrui Medicine Co.Ltd. Basic Information
10.8.2 Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Overview
10.8.3 Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Market Performance
10.8.4 Jiangsu Hengrui Medicine Co.Ltd. Business Overview
10.8.5 Jiangsu Hengrui Medicine Co.Ltd. Recent Developments
10.9 Karyopharm TherapeuticsInc.
10.9.1 Karyopharm TherapeuticsInc. Basic Information
10.9.2 Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
10.9.3 Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Market Performance
10.9.4 Karyopharm TherapeuticsInc. Business Overview
10.9.5 Karyopharm TherapeuticsInc. Recent Developments
10.10 Lexicon PharmaceuticalsInc.
10.10.1 Lexicon PharmaceuticalsInc. Basic Information
10.10.2 Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.10.3 Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.10.4 Lexicon PharmaceuticalsInc. Business Overview
10.10.5 Lexicon PharmaceuticalsInc. Recent Developments
10.11 Midatech Pharma Plc .
10.11.1 Midatech Pharma Plc . Basic Information
10.11.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Overview
10.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Market Performance
10.11.4 Midatech Pharma Plc . Business Overview
10.11.5 Midatech Pharma Plc . Recent Developments
10.12 Millennium PharmaceuticalsInc.
10.12.1 Millennium PharmaceuticalsInc. Basic Information
10.12.2 Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.12.3 Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.12.4 Millennium PharmaceuticalsInc. Business Overview
10.12.5 Millennium PharmaceuticalsInc. Recent Developments
10.13 MolMed S.p.A.
10.13.1 MolMed S.p.A. Basic Information
10.13.2 MolMed S.p.A. Neuroendocrine Tumor Drug Product Overview
10.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Product Market Performance
10.13.4 MolMed S.p.A. Business Overview
10.13.5 MolMed S.p.A. Recent Developments
10.14 Northwest BiotherapeuticsInc.
10.14.1 Northwest BiotherapeuticsInc. Basic Information
10.14.2 Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
10.14.3 Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Market Performance
10.14.4 Northwest BiotherapeuticsInc. Business Overview
10.14.5 Northwest BiotherapeuticsInc. Recent Developments
10.15 Novartis AG
10.15.1 Novartis AG Basic Information
10.15.2 Novartis AG Neuroendocrine Tumor Drug Product Overview
10.15.3 Novartis AG Neuroendocrine Tumor Drug Product Market Performance
10.15.4 Novartis AG Business Overview
10.15.5 Novartis AG Recent Developments
10.16 OctreoPharm Sciences GmbH
10.16.1 OctreoPharm Sciences GmbH Basic Information
10.16.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Overview
10.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Market Performance
10.16.4 OctreoPharm Sciences GmbH Business Overview
10.16.5 OctreoPharm Sciences GmbH Recent Developments
10.17 OXiGENEInc.
10.17.1 OXiGENEInc. Basic Information
10.17.2 OXiGENEInc. Neuroendocrine Tumor Drug Product Overview
10.17.3 OXiGENEInc. Neuroendocrine Tumor Drug Product Market Performance
10.17.4 OXiGENEInc. Business Overview
10.17.5 OXiGENEInc. Recent Developments
11 NEUROENDOCRINE TUMOR DRUG MARKET FORECAST BY REGION
11.1 Global Neuroendocrine Tumor Drug Market Size Forecast
11.2 Global Neuroendocrine Tumor Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neuroendocrine Tumor Drug Market Size Forecast by Country
11.2.3 Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast by Region
11.2.4 South America Neuroendocrine Tumor Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neuroendocrine Tumor Drug by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Neuroendocrine Tumor Drug Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Neuroendocrine Tumor Drug by Type (2026-2033)
12.1.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Neuroendocrine Tumor Drug by Type (2026-2033)
12.2 Global Neuroendocrine Tumor Drug Market Forecast by Application (2026-2033)
12.2.1 Global Neuroendocrine Tumor Drug Sales (K MT) Forecast by Application
12.2.2 Global Neuroendocrine Tumor Drug Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neuroendocrine Tumor Drug
1.2 Key Market Segments
1.2.1 Neuroendocrine Tumor Drug Segment by Type
1.2.2 Neuroendocrine Tumor Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEUROENDOCRINE TUMOR DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neuroendocrine Tumor Drug Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEUROENDOCRINE TUMOR DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neuroendocrine Tumor Drug Product Life Cycle
3.3 Global Neuroendocrine Tumor Drug Sales by Manufacturers (2020-2025)
3.4 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neuroendocrine Tumor Drug Market Competitive Situation and Trends
3.8.1 Neuroendocrine Tumor Drug Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neuroendocrine Tumor Drug Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEUROENDOCRINE TUMOR DRUG INDUSTRY CHAIN ANALYSIS
4.1 Neuroendocrine Tumor Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEUROENDOCRINE TUMOR DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neuroendocrine Tumor Drug Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neuroendocrine Tumor Drug Market
5.7 ESG Ratings of Leading Companies
6 NEUROENDOCRINE TUMOR DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
6.3 Global Neuroendocrine Tumor Drug Market Size Market Share by Type (2020-2025)
6.4 Global Neuroendocrine Tumor Drug Price by Type (2020-2025)
7 NEUROENDOCRINE TUMOR DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neuroendocrine Tumor Drug Market Sales by Application (2020-2025)
7.3 Global Neuroendocrine Tumor Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
8 NEUROENDOCRINE TUMOR DRUG MARKET SALES BY REGION
8.1 Global Neuroendocrine Tumor Drug Sales by Region
8.1.1 Global Neuroendocrine Tumor Drug Sales by Region
8.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Region
8.2 Global Neuroendocrine Tumor Drug Market Size by Region
8.2.1 Global Neuroendocrine Tumor Drug Market Size by Region
8.2.2 Global Neuroendocrine Tumor Drug Market Size Market Share by Region
8.3 North America
8.3.1 North America Neuroendocrine Tumor Drug Sales by Country
8.3.2 North America Neuroendocrine Tumor Drug Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neuroendocrine Tumor Drug Sales by Country
8.4.2 Europe Neuroendocrine Tumor Drug Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region
8.5.2 Asia Pacific Neuroendocrine Tumor Drug Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neuroendocrine Tumor Drug Sales by Country
8.6.2 South America Neuroendocrine Tumor Drug Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Region
8.7.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEUROENDOCRINE TUMOR DRUG MARKET PRODUCTION BY REGION
9.1 Global Production of Neuroendocrine Tumor Drug by Region(2020-2025)
9.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
9.3 Global Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neuroendocrine Tumor Drug Production
9.4.1 North America Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.4.2 North America Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neuroendocrine Tumor Drug Production
9.5.1 Europe Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.5.2 Europe Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neuroendocrine Tumor Drug Production (2020-2025)
9.6.1 Japan Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.6.2 Japan Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neuroendocrine Tumor Drug Production (2020-2025)
9.7.1 China Neuroendocrine Tumor Drug Production Growth Rate (2020-2025)
9.7.2 China Neuroendocrine Tumor Drug Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Eisai
10.1.1 Eisai Basic Information
10.1.2 Eisai Neuroendocrine Tumor Drug Product Overview
10.1.3 Eisai Neuroendocrine Tumor Drug Product Market Performance
10.1.4 Eisai Business Overview
10.1.5 Eisai SWOT Analysis
10.1.6 Eisai Recent Developments
10.2 ExelixisInc.
10.2.1 ExelixisInc. Basic Information
10.2.2 ExelixisInc. Neuroendocrine Tumor Drug Product Overview
10.2.3 ExelixisInc. Neuroendocrine Tumor Drug Product Market Performance
10.2.4 ExelixisInc. Business Overview
10.2.5 ExelixisInc. SWOT Analysis
10.2.6 ExelixisInc. Recent Developments
10.3 Foresee PharmaceuticalsLLC
10.3.1 Foresee PharmaceuticalsLLC Basic Information
10.3.2 Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Overview
10.3.3 Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Market Performance
10.3.4 Foresee PharmaceuticalsLLC Business Overview
10.3.5 Foresee PharmaceuticalsLLC SWOT Analysis
10.3.6 Foresee PharmaceuticalsLLC Recent Developments
10.4 Hutchison MediPharma Limited
10.4.1 Hutchison MediPharma Limited Basic Information
10.4.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Overview
10.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Market Performance
10.4.4 Hutchison MediPharma Limited Business Overview
10.4.5 Hutchison MediPharma Limited Recent Developments
10.5 IntezyneInc
10.5.1 IntezyneInc Basic Information
10.5.2 IntezyneInc Neuroendocrine Tumor Drug Product Overview
10.5.3 IntezyneInc Neuroendocrine Tumor Drug Product Market Performance
10.5.4 IntezyneInc Business Overview
10.5.5 IntezyneInc Recent Developments
10.6 INVENT PharmaceuticalsInc.
10.6.1 INVENT PharmaceuticalsInc. Basic Information
10.6.2 INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.6.3 INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.6.4 INVENT PharmaceuticalsInc. Business Overview
10.6.5 INVENT PharmaceuticalsInc. Recent Developments
10.7 Ipsen S.A.
10.7.1 Ipsen S.A. Basic Information
10.7.2 Ipsen S.A. Neuroendocrine Tumor Drug Product Overview
10.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Product Market Performance
10.7.4 Ipsen S.A. Business Overview
10.7.5 Ipsen S.A. Recent Developments
10.8 Jiangsu Hengrui Medicine Co.Ltd.
10.8.1 Jiangsu Hengrui Medicine Co.Ltd. Basic Information
10.8.2 Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Overview
10.8.3 Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Market Performance
10.8.4 Jiangsu Hengrui Medicine Co.Ltd. Business Overview
10.8.5 Jiangsu Hengrui Medicine Co.Ltd. Recent Developments
10.9 Karyopharm TherapeuticsInc.
10.9.1 Karyopharm TherapeuticsInc. Basic Information
10.9.2 Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
10.9.3 Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Market Performance
10.9.4 Karyopharm TherapeuticsInc. Business Overview
10.9.5 Karyopharm TherapeuticsInc. Recent Developments
10.10 Lexicon PharmaceuticalsInc.
10.10.1 Lexicon PharmaceuticalsInc. Basic Information
10.10.2 Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.10.3 Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.10.4 Lexicon PharmaceuticalsInc. Business Overview
10.10.5 Lexicon PharmaceuticalsInc. Recent Developments
10.11 Midatech Pharma Plc .
10.11.1 Midatech Pharma Plc . Basic Information
10.11.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Overview
10.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Market Performance
10.11.4 Midatech Pharma Plc . Business Overview
10.11.5 Midatech Pharma Plc . Recent Developments
10.12 Millennium PharmaceuticalsInc.
10.12.1 Millennium PharmaceuticalsInc. Basic Information
10.12.2 Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
10.12.3 Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Market Performance
10.12.4 Millennium PharmaceuticalsInc. Business Overview
10.12.5 Millennium PharmaceuticalsInc. Recent Developments
10.13 MolMed S.p.A.
10.13.1 MolMed S.p.A. Basic Information
10.13.2 MolMed S.p.A. Neuroendocrine Tumor Drug Product Overview
10.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Product Market Performance
10.13.4 MolMed S.p.A. Business Overview
10.13.5 MolMed S.p.A. Recent Developments
10.14 Northwest BiotherapeuticsInc.
10.14.1 Northwest BiotherapeuticsInc. Basic Information
10.14.2 Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
10.14.3 Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Market Performance
10.14.4 Northwest BiotherapeuticsInc. Business Overview
10.14.5 Northwest BiotherapeuticsInc. Recent Developments
10.15 Novartis AG
10.15.1 Novartis AG Basic Information
10.15.2 Novartis AG Neuroendocrine Tumor Drug Product Overview
10.15.3 Novartis AG Neuroendocrine Tumor Drug Product Market Performance
10.15.4 Novartis AG Business Overview
10.15.5 Novartis AG Recent Developments
10.16 OctreoPharm Sciences GmbH
10.16.1 OctreoPharm Sciences GmbH Basic Information
10.16.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Overview
10.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Market Performance
10.16.4 OctreoPharm Sciences GmbH Business Overview
10.16.5 OctreoPharm Sciences GmbH Recent Developments
10.17 OXiGENEInc.
10.17.1 OXiGENEInc. Basic Information
10.17.2 OXiGENEInc. Neuroendocrine Tumor Drug Product Overview
10.17.3 OXiGENEInc. Neuroendocrine Tumor Drug Product Market Performance
10.17.4 OXiGENEInc. Business Overview
10.17.5 OXiGENEInc. Recent Developments
11 NEUROENDOCRINE TUMOR DRUG MARKET FORECAST BY REGION
11.1 Global Neuroendocrine Tumor Drug Market Size Forecast
11.2 Global Neuroendocrine Tumor Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neuroendocrine Tumor Drug Market Size Forecast by Country
11.2.3 Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast by Region
11.2.4 South America Neuroendocrine Tumor Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neuroendocrine Tumor Drug by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Neuroendocrine Tumor Drug Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Neuroendocrine Tumor Drug by Type (2026-2033)
12.1.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Neuroendocrine Tumor Drug by Type (2026-2033)
12.2 Global Neuroendocrine Tumor Drug Market Forecast by Application (2026-2033)
12.2.1 Global Neuroendocrine Tumor Drug Sales (K MT) Forecast by Application
12.2.2 Global Neuroendocrine Tumor Drug Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neuroendocrine Tumor Drug Market Size Comparison by Region (M USD)
Table 5. Global Neuroendocrine Tumor Drug Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Neuroendocrine Tumor Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Tumor Drug as of 2024)
Table 10. Global Market Neuroendocrine Tumor Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Neuroendocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Neuroendocrine Tumor Drug Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Neuroendocrine Tumor Drug Sales by Type (K MT)
Table 26. Global Neuroendocrine Tumor Drug Market Size by Type (M USD)
Table 27. Global Neuroendocrine Tumor Drug Sales (K MT) by Type (2020-2025)
Table 28. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Table 29. Global Neuroendocrine Tumor Drug Market Size (M USD) by Type (2020-2025)
Table 30. Global Neuroendocrine Tumor Drug Market Size Share by Type (2020-2025)
Table 31. Global Neuroendocrine Tumor Drug Price (USD/KG) by Type (2020-2025)
Table 32. Global Neuroendocrine Tumor Drug Sales (K MT) by Application
Table 33. Global Neuroendocrine Tumor Drug Market Size by Application
Table 34. Global Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K MT)
Table 35. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Table 36. Global Neuroendocrine Tumor Drug Market Size by Application (2020-2025) & (M USD)
Table 37. Global Neuroendocrine Tumor Drug Market Share by Application (2020-2025)
Table 38. Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
Table 39. Global Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 40. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
Table 41. Global Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 42. Global Neuroendocrine Tumor Drug Market Size Market Share by Region (2020-2025)
Table 43. North America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 44. North America Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 46. Europe Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 49. South America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 50. South America Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 53. Global Neuroendocrine Tumor Drug Production (K MT) by Region(2020-2025)
Table 54. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
Table 56. Global Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Eisai Basic Information
Table 62. Eisai Neuroendocrine Tumor Drug Product Overview
Table 63. Eisai Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Eisai Business Overview
Table 65. Eisai SWOT Analysis
Table 66. Eisai Recent Developments
Table 67. ExelixisInc. Basic Information
Table 68. ExelixisInc. Neuroendocrine Tumor Drug Product Overview
Table 69. ExelixisInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. ExelixisInc. Business Overview
Table 71. ExelixisInc. SWOT Analysis
Table 72. ExelixisInc. Recent Developments
Table 73. Foresee PharmaceuticalsLLC Basic Information
Table 74. Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Overview
Table 75. Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Foresee PharmaceuticalsLLC Business Overview
Table 77. Foresee PharmaceuticalsLLC SWOT Analysis
Table 78. Foresee PharmaceuticalsLLC Recent Developments
Table 79. Hutchison MediPharma Limited Basic Information
Table 80. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Overview
Table 81. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. Hutchison MediPharma Limited Business Overview
Table 83. Hutchison MediPharma Limited Recent Developments
Table 84. IntezyneInc Basic Information
Table 85. IntezyneInc Neuroendocrine Tumor Drug Product Overview
Table 86. IntezyneInc Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. IntezyneInc Business Overview
Table 88. IntezyneInc Recent Developments
Table 89. INVENT PharmaceuticalsInc. Basic Information
Table 90. INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 91. INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. INVENT PharmaceuticalsInc. Business Overview
Table 93. INVENT PharmaceuticalsInc. Recent Developments
Table 94. Ipsen S.A. Basic Information
Table 95. Ipsen S.A. Neuroendocrine Tumor Drug Product Overview
Table 96. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Ipsen S.A. Business Overview
Table 98. Ipsen S.A. Recent Developments
Table 99. Jiangsu Hengrui Medicine Co.Ltd. Basic Information
Table 100. Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Overview
Table 101. Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Jiangsu Hengrui Medicine Co.Ltd. Business Overview
Table 103. Jiangsu Hengrui Medicine Co.Ltd. Recent Developments
Table 104. Karyopharm TherapeuticsInc. Basic Information
Table 105. Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
Table 106. Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Karyopharm TherapeuticsInc. Business Overview
Table 108. Karyopharm TherapeuticsInc. Recent Developments
Table 109. Lexicon PharmaceuticalsInc. Basic Information
Table 110. Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 111. Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Lexicon PharmaceuticalsInc. Business Overview
Table 113. Lexicon PharmaceuticalsInc. Recent Developments
Table 114. Midatech Pharma Plc . Basic Information
Table 115. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Overview
Table 116. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Midatech Pharma Plc . Business Overview
Table 118. Midatech Pharma Plc . Recent Developments
Table 119. Millennium PharmaceuticalsInc. Basic Information
Table 120. Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 121. Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Millennium PharmaceuticalsInc. Business Overview
Table 123. Millennium PharmaceuticalsInc. Recent Developments
Table 124. MolMed S.p.A. Basic Information
Table 125. MolMed S.p.A. Neuroendocrine Tumor Drug Product Overview
Table 126. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. MolMed S.p.A. Business Overview
Table 128. MolMed S.p.A. Recent Developments
Table 129. Northwest BiotherapeuticsInc. Basic Information
Table 130. Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
Table 131. Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Northwest BiotherapeuticsInc. Business Overview
Table 133. Northwest BiotherapeuticsInc. Recent Developments
Table 134. Novartis AG Basic Information
Table 135. Novartis AG Neuroendocrine Tumor Drug Product Overview
Table 136. Novartis AG Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Novartis AG Business Overview
Table 138. Novartis AG Recent Developments
Table 139. OctreoPharm Sciences GmbH Basic Information
Table 140. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Overview
Table 141. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. OctreoPharm Sciences GmbH Business Overview
Table 143. OctreoPharm Sciences GmbH Recent Developments
Table 144. OXiGENEInc. Basic Information
Table 145. OXiGENEInc. Neuroendocrine Tumor Drug Product Overview
Table 146. OXiGENEInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. OXiGENEInc. Business Overview
Table 148. OXiGENEInc. Recent Developments
Table 149. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 150. Global Neuroendocrine Tumor Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 151. North America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 152. North America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 153. Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 154. Europe Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 155. Asia Pacific Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 156. Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 157. South America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 158. South America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 159. Middle East and Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (Units)
Table 160. Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 161. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2026-2033) & (K MT)
Table 162. Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2026-2033) & (M USD)
Table 163. Global Neuroendocrine Tumor Drug Price Forecast by Type (2026-2033) & (USD/KG)
Table 164. Global Neuroendocrine Tumor Drug Sales (K MT) Forecast by Application (2026-2033)
Table 165. Global Neuroendocrine Tumor Drug Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neuroendocrine Tumor Drug Market Size Comparison by Region (M USD)
Table 5. Global Neuroendocrine Tumor Drug Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Neuroendocrine Tumor Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Tumor Drug as of 2024)
Table 10. Global Market Neuroendocrine Tumor Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Neuroendocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Neuroendocrine Tumor Drug Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Neuroendocrine Tumor Drug Sales by Type (K MT)
Table 26. Global Neuroendocrine Tumor Drug Market Size by Type (M USD)
Table 27. Global Neuroendocrine Tumor Drug Sales (K MT) by Type (2020-2025)
Table 28. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Table 29. Global Neuroendocrine Tumor Drug Market Size (M USD) by Type (2020-2025)
Table 30. Global Neuroendocrine Tumor Drug Market Size Share by Type (2020-2025)
Table 31. Global Neuroendocrine Tumor Drug Price (USD/KG) by Type (2020-2025)
Table 32. Global Neuroendocrine Tumor Drug Sales (K MT) by Application
Table 33. Global Neuroendocrine Tumor Drug Market Size by Application
Table 34. Global Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K MT)
Table 35. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Table 36. Global Neuroendocrine Tumor Drug Market Size by Application (2020-2025) & (M USD)
Table 37. Global Neuroendocrine Tumor Drug Market Share by Application (2020-2025)
Table 38. Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
Table 39. Global Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 40. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
Table 41. Global Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 42. Global Neuroendocrine Tumor Drug Market Size Market Share by Region (2020-2025)
Table 43. North America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 44. North America Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 46. Europe Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 49. South America Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K MT)
Table 50. South America Neuroendocrine Tumor Drug Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Neuroendocrine Tumor Drug Market Size by Region (2020-2025) & (M USD)
Table 53. Global Neuroendocrine Tumor Drug Production (K MT) by Region(2020-2025)
Table 54. Global Neuroendocrine Tumor Drug Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
Table 56. Global Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Neuroendocrine Tumor Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Eisai Basic Information
Table 62. Eisai Neuroendocrine Tumor Drug Product Overview
Table 63. Eisai Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Eisai Business Overview
Table 65. Eisai SWOT Analysis
Table 66. Eisai Recent Developments
Table 67. ExelixisInc. Basic Information
Table 68. ExelixisInc. Neuroendocrine Tumor Drug Product Overview
Table 69. ExelixisInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. ExelixisInc. Business Overview
Table 71. ExelixisInc. SWOT Analysis
Table 72. ExelixisInc. Recent Developments
Table 73. Foresee PharmaceuticalsLLC Basic Information
Table 74. Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Product Overview
Table 75. Foresee PharmaceuticalsLLC Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Foresee PharmaceuticalsLLC Business Overview
Table 77. Foresee PharmaceuticalsLLC SWOT Analysis
Table 78. Foresee PharmaceuticalsLLC Recent Developments
Table 79. Hutchison MediPharma Limited Basic Information
Table 80. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Overview
Table 81. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. Hutchison MediPharma Limited Business Overview
Table 83. Hutchison MediPharma Limited Recent Developments
Table 84. IntezyneInc Basic Information
Table 85. IntezyneInc Neuroendocrine Tumor Drug Product Overview
Table 86. IntezyneInc Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. IntezyneInc Business Overview
Table 88. IntezyneInc Recent Developments
Table 89. INVENT PharmaceuticalsInc. Basic Information
Table 90. INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 91. INVENT PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. INVENT PharmaceuticalsInc. Business Overview
Table 93. INVENT PharmaceuticalsInc. Recent Developments
Table 94. Ipsen S.A. Basic Information
Table 95. Ipsen S.A. Neuroendocrine Tumor Drug Product Overview
Table 96. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Ipsen S.A. Business Overview
Table 98. Ipsen S.A. Recent Developments
Table 99. Jiangsu Hengrui Medicine Co.Ltd. Basic Information
Table 100. Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Product Overview
Table 101. Jiangsu Hengrui Medicine Co.Ltd. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Jiangsu Hengrui Medicine Co.Ltd. Business Overview
Table 103. Jiangsu Hengrui Medicine Co.Ltd. Recent Developments
Table 104. Karyopharm TherapeuticsInc. Basic Information
Table 105. Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
Table 106. Karyopharm TherapeuticsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Karyopharm TherapeuticsInc. Business Overview
Table 108. Karyopharm TherapeuticsInc. Recent Developments
Table 109. Lexicon PharmaceuticalsInc. Basic Information
Table 110. Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 111. Lexicon PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Lexicon PharmaceuticalsInc. Business Overview
Table 113. Lexicon PharmaceuticalsInc. Recent Developments
Table 114. Midatech Pharma Plc . Basic Information
Table 115. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Overview
Table 116. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Midatech Pharma Plc . Business Overview
Table 118. Midatech Pharma Plc . Recent Developments
Table 119. Millennium PharmaceuticalsInc. Basic Information
Table 120. Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Product Overview
Table 121. Millennium PharmaceuticalsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Millennium PharmaceuticalsInc. Business Overview
Table 123. Millennium PharmaceuticalsInc. Recent Developments
Table 124. MolMed S.p.A. Basic Information
Table 125. MolMed S.p.A. Neuroendocrine Tumor Drug Product Overview
Table 126. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. MolMed S.p.A. Business Overview
Table 128. MolMed S.p.A. Recent Developments
Table 129. Northwest BiotherapeuticsInc. Basic Information
Table 130. Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Product Overview
Table 131. Northwest BiotherapeuticsInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Northwest BiotherapeuticsInc. Business Overview
Table 133. Northwest BiotherapeuticsInc. Recent Developments
Table 134. Novartis AG Basic Information
Table 135. Novartis AG Neuroendocrine Tumor Drug Product Overview
Table 136. Novartis AG Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Novartis AG Business Overview
Table 138. Novartis AG Recent Developments
Table 139. OctreoPharm Sciences GmbH Basic Information
Table 140. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Overview
Table 141. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. OctreoPharm Sciences GmbH Business Overview
Table 143. OctreoPharm Sciences GmbH Recent Developments
Table 144. OXiGENEInc. Basic Information
Table 145. OXiGENEInc. Neuroendocrine Tumor Drug Product Overview
Table 146. OXiGENEInc. Neuroendocrine Tumor Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. OXiGENEInc. Business Overview
Table 148. OXiGENEInc. Recent Developments
Table 149. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 150. Global Neuroendocrine Tumor Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 151. North America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 152. North America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 153. Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 154. Europe Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 155. Asia Pacific Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2033) & (K MT)
Table 156. Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast by Region (2026-2033) & (M USD)
Table 157. South America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (K MT)
Table 158. South America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 159. Middle East and Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2033) & (Units)
Table 160. Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2033) & (M USD)
Table 161. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2026-2033) & (K MT)
Table 162. Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2026-2033) & (M USD)
Table 163. Global Neuroendocrine Tumor Drug Price Forecast by Type (2026-2033) & (USD/KG)
Table 164. Global Neuroendocrine Tumor Drug Sales (K MT) Forecast by Application (2026-2033)
Table 165. Global Neuroendocrine Tumor Drug Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neuroendocrine Tumor Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neuroendocrine Tumor Drug Market Size (M USD), 2024-2033
Figure 5. Global Neuroendocrine Tumor Drug Market Size (M USD) (2020-2033)
Figure 6. Global Neuroendocrine Tumor Drug Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neuroendocrine Tumor Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neuroendocrine Tumor Drug Product Life Cycle
Figure 13. Neuroendocrine Tumor Drug Sales Share by Manufacturers in 2024
Figure 14. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers in 2024
Figure 15. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Neuroendocrine Tumor Drug Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neuroendocrine Tumor Drug Revenue in 2024
Figure 18. Industry Chain Map of Neuroendocrine Tumor Drug
Figure 19. Global Neuroendocrine Tumor Drug Market PEST Analysis
Figure 20. Global Neuroendocrine Tumor Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neuroendocrine Tumor Drug Market Share by Type
Figure 27. Sales Market Share of Neuroendocrine Tumor Drug by Type (2020-2025)
Figure 28. Sales Market Share of Neuroendocrine Tumor Drug by Type in 2024
Figure 29. Market Size Share of Neuroendocrine Tumor Drug by Type (2020-2025)
Figure 30. Market Size Share of Neuroendocrine Tumor Drug by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neuroendocrine Tumor Drug Market Share by Application
Figure 33. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2024
Figure 35. Global Neuroendocrine Tumor Drug Market Share by Application (2020-2025)
Figure 36. Global Neuroendocrine Tumor Drug Market Share by Application in 2024
Figure 37. Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Neuroendocrine Tumor Drug Market Size Market Share by Region (2020-2025)
Figure 40. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 43. North America Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 45. U.S. Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neuroendocrine Tumor Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neuroendocrine Tumor Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neuroendocrine Tumor Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neuroendocrine Tumor Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 53. Europe Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 55. Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neuroendocrine Tumor Drug Market Size Market Share by Region in 2024
Figure 68. China Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 79. South America Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 80. South America Neuroendocrine Tumor Drug Market Size and Growth Rate (M USD)
Figure 81. South America Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 82. Brazil Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neuroendocrine Tumor Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neuroendocrine Tumor Drug Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neuroendocrine Tumor Drug Production Market Share by Region (2020-2025)
Figure 103. North America Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neuroendocrine Tumor Drug Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Neuroendocrine Tumor Drug Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Neuroendocrine Tumor Drug Market Share Forecast by Type (2026-2033)
Figure 111. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2026-2033)
Figure 112. Global Neuroendocrine Tumor Drug Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Neuroendocrine Tumor Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neuroendocrine Tumor Drug Market Size (M USD), 2024-2033
Figure 5. Global Neuroendocrine Tumor Drug Market Size (M USD) (2020-2033)
Figure 6. Global Neuroendocrine Tumor Drug Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neuroendocrine Tumor Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neuroendocrine Tumor Drug Product Life Cycle
Figure 13. Neuroendocrine Tumor Drug Sales Share by Manufacturers in 2024
Figure 14. Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers in 2024
Figure 15. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Neuroendocrine Tumor Drug Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neuroendocrine Tumor Drug Revenue in 2024
Figure 18. Industry Chain Map of Neuroendocrine Tumor Drug
Figure 19. Global Neuroendocrine Tumor Drug Market PEST Analysis
Figure 20. Global Neuroendocrine Tumor Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neuroendocrine Tumor Drug Market Share by Type
Figure 27. Sales Market Share of Neuroendocrine Tumor Drug by Type (2020-2025)
Figure 28. Sales Market Share of Neuroendocrine Tumor Drug by Type in 2024
Figure 29. Market Size Share of Neuroendocrine Tumor Drug by Type (2020-2025)
Figure 30. Market Size Share of Neuroendocrine Tumor Drug by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neuroendocrine Tumor Drug Market Share by Application
Figure 33. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2024
Figure 35. Global Neuroendocrine Tumor Drug Market Share by Application (2020-2025)
Figure 36. Global Neuroendocrine Tumor Drug Market Share by Application in 2024
Figure 37. Global Neuroendocrine Tumor Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Neuroendocrine Tumor Drug Market Size Market Share by Region (2020-2025)
Figure 40. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 43. North America Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 45. U.S. Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neuroendocrine Tumor Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neuroendocrine Tumor Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neuroendocrine Tumor Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neuroendocrine Tumor Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 53. Europe Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 55. Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neuroendocrine Tumor Drug Market Size Market Share by Region in 2024
Figure 68. China Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 79. South America Neuroendocrine Tumor Drug Sales Market Share by Country in 2024
Figure 80. South America Neuroendocrine Tumor Drug Market Size and Growth Rate (M USD)
Figure 81. South America Neuroendocrine Tumor Drug Market Size Market Share by Country in 2024
Figure 82. Brazil Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neuroendocrine Tumor Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neuroendocrine Tumor Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neuroendocrine Tumor Drug Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neuroendocrine Tumor Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neuroendocrine Tumor Drug Production Market Share by Region (2020-2025)
Figure 103. North America Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neuroendocrine Tumor Drug Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neuroendocrine Tumor Drug Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Neuroendocrine Tumor Drug Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Neuroendocrine Tumor Drug Market Share Forecast by Type (2026-2033)
Figure 111. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2026-2033)
Figure 112. Global Neuroendocrine Tumor Drug Market Share Forecast by Application (2026-2033)
